The TRANSVAC Steering Committee is the main and final decision making body in the partnership and is responsible for:
- Monitoring and discussing the progress of the overall strategic objectives of the initiative.
- Ensuring that the work package framework proposed within this document is implemented.
- Taking the decisions needed to effectively implement the work programme and achieve the deliverables and milestones.
- Facilitating any changes and/or additions to the partners involved in the initiative.
- Discussion and agreement on the financial allocation and distribution of resources according to the proposed work programme.
- Initial arbitration of any issues that could not be resolved within the working groups.
Dr Odile Leroy (Chair)
European Vaccine Initiative
Odile has been the Executive Director of the European Vaccine Initiative (EVI), formerly European Malaria Vaccine Initiative (EMVI) since 2006. Odile has spent most of her career in vaccine development, as a scientist in Africa for nine years, followed by Corporate Clinical Director of airborne vaccines for ten years at Pasteur Mérieux Connaught (Sanofi Pasteur). She joined EMVI in 2002 as Clinical and Regulatory Affairs Director, and from 2005 to 2006, she headed the European and Developing Countries’ Clinical Trial Partnership as Executive Director. Odile is a member of the Science Board of the Brighton Collaboration, coordinator of three EC FP7 consortia, including the vaccine infrastructure project TRANSVAC, and a member of the WHO product development group for the measles aerosol project. Odile is a trained physician who has specialised in the areas of epidemiology, clinical pharmacology, and vaccinology.
Prof Mahavir Singh (Vice Chair)
Prof Dr Carlos Guzmán
Helmholtz Centre for Infection Research, Germany
Carlos A. Guzmán Prof., MD, Ph.D. is the Head of the Department of Vaccinology and Applied Microbiology at the Helmholtz Centre for Infection Research (HZI; Braunschweig, Germany) and APL-Professor at the Medical School of Hannover. He is also external lecturer of the Doctorate in Biotechnology from the University of Catania (Italy) and Speaker for the Topic “Prevention & Therapy” within the “Infection Research” Program of the Helmholtz Association. He graduated in Medicine at the National University of Rosario and obtained his Board Certification in Medical Bacteriology in Argentina. Then, he moved to the Institute of Microbiology from the University of Genoa (Italy), as Research Fellow from the Italian Foreign Office Ministry. In Italy he also graduated as Doctor of Medicine and Surgery and obtained his Doctorate of Research in Microbiological Sciences. In 1994 he moved to Germany, where he became Head of the Vaccine Research Group at the German Research Centre for Biotechnology. In 2005 he was appointed as Head of the new HZI Department of Vaccinology. He has been working in the field of Vaccinology since 1989. His work has been instrumental for the development of new adjuvants and mucosal antigen delivery systems.
Dr Ed Remarque
Biomedical Primate Research Center
Dr Remarque obtained his masters degree in Medical Biology at Leiden University in 1988 and started as a research scientist at the Section of Gerontology and Geriatrics, Leiden University. He obtained his PhD on the humoral response to influenza vaccination in the elderly in 1996. In 2002 he joined the BPRC to work on the clinical development of an Apical Membrane Antigen 1-based (AMA1) malaria vaccine. His main research interests are: vaccine design, vaccine development, infectious diseases, adjuvant selection, animal studies, assay harmonisation, statistics and epidemiology.
Dr Jan Langermans
Central Veterinary Institute, Wageningen UR
Jan A.M. Langermans, Ph.D., has been Chairman of the Animal Science Department, BPRC, Rijswijk, The Netherlands since 2008. His research interests include the development of animal models for infectious disease research, vaccine development, and immunology. Jan received his Ph.D. in 1992 in Leiden (with honours), and was Assistant Professor at LUMC in Leiden from 1992 to 1996. He headed the Parasitic and Bacterial Immunology Department at BPRC, Rijswijk from 1996-2003, covering malaria, TB and schistosoma research. Jan was Director of the Experimental Animal Services and BioMedical Research, ASG Wageningen UR, Lelystad between 2003-2008.
Dr Jelle Thole
TuBerculosis Vaccine Initiative
Dr Jelle Thole is Founder and Director of the TuBerculosis Vaccine Initiative (TBVI), a not for profit foundation based in Lelystad, the Netherlands, which aims to develop new vaccines against tuberculosis. He coordinates an international consortium of over 50 universities, institutes and industries via several research projects; among others the EU FP7 funded NEWTBVAC project, focusing on the discovery and preclinical testing of new tuberculosis vaccine candidates. Furthermore he coordinates a North-South European-African network (TB-TEA) on clinical trials capacity building funded by EDCTP. Jelle Thole is Chair of Vaccine Program Advisory Group (VPAG) advising DEFRA on a vaccine program against bovine TB in the UK, is member of the Vaccine Core Group of the Working Group for NEW TB vaccines of the STOP TB Partnership and is Section Editor of the Journal Tuberculosis. Jelle Thole graduated in medical biology in 1984, PhD in Medicine in 1988 and has more than 25 years of experience in molecular and immunological research on mycobacteria. He is author of over 70 scientific articles on antigen discovery, host-pathogen interactions, and immunology of human and veterinary mycobacterial pathogens including tuberculosis and leprosy.
Dr Mei Mei Ho
HPA National Institute for Biological Standards and Control
Dr Mei Mei Ho is a Principal Scientist in the Bacteriology Division at the National Institute for Biological Standards and Control (NIBSC), a centre of the Health Protection Agency (HPA), UK. She has a broad experience in bacterial vaccines and leads a team focuses on R&D, quality control (ISO/IEC 17025 accredited) and standardisation of biological medicines used in tuberculosis, malaria and healthcare associated infections. She is a member of the Product Development Team in TB Vaccine Initiative and the World Health Organization (WHO) BCG working group, and provides regulatory advice on vaccine safety, quality and characterisation to vaccine developers and manufacturers.
Dr Nicolas Collin
University of Lausanne
Nicolas Collin is Head of the Vaccine Formulation Laboratory at University of Lausanne, Switzerland. The laboratory is a platform for global access to vaccine adjuvants and a training centre for vaccine formulation. Formerly, Dr Collin was technical officer at the World Health Organization (WHO), Geneva, and coordinator of the WHO vaccine task force during the pandemic influenza (H1N1) in 2009. Prior to this, he worked four years as project leader for the industry (Merial, Lyon) and completed a post-doctoral training at the National Institutes of Health (NIH) on Leishmania vaccines. Nicolas Collin is Doctor in Veterinary Medicine (National Veterinary School of Toulouse) and holds a PhD in Molecular Virology (University of Toulouse III).